11 results · 24ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

uCT 550

FDA 510(k)
FDA Class 2 ·Radiology

ONE TOUCH BASIC ENHANCED

FDA Adverse Event
Malfunction ·LIFESCAN, INC.·Product code CFR·July 23, 2002

SIEMENS ENHANCED IMAGING SYSTEM

FDA 510(k)
FDA Class 2 ·Radiology

Temno Elite Biopsy System

FDA 510(k)
FDA Class 2 ·Gastroenterology, Urology

DIGITALDIAGNOST C90 HIGHPERFORMANCE

FDA Adverse Event
Malfunction ·PHILIPS MEDICAL SYSTEMS DMC GMBH·Product code MQB·June 17, 2024

ALARIS SYSTEM

FDA Adverse Event
Malfunction ·CAREFUSION SD·Product code FRN·October 27, 2023

PULSE GEN MODEL 101

FDA Adverse Event
Injury ·CYBERONICS, INC.·Product code LYJ·November 20, 2008

840 VENTILATOR

FDA Adverse Event
Malfunction ·COVIDIEN, FORMERLY NELLCOR·Product code CBK·August 17, 2011

SETROX S 53

FDA Adverse Event
Malfunction ·BIOTRONIK SE & CO. KG·Product code NVN·July 22, 2013

ANTERALIGN¿ SPINAL SYSTEM WITH TITAN NANOLOCK¿ SURFACE TECHNOLOGY

FDA Adverse Event
Malfunction ·MEDTRONIC SOFAMOR DANEK USA, INC.·Product code MAX·March 2, 2026

Boston Scientific TELIGEN, Implantable Cardiac Defibrillator models E102, E110, the following models are not available in the US: models E103, E111, F102, F103, F110, F111. Sterilized using ethylene oxide. Product Usage: This family of implantable cardioverter defibrillators (ICDs) provide a variety of therapies including: -Ventricular tachyarrhythmia therapy, which is used to treat rhythms associated with sudden cardiac death such as VT and VF; -Bradycardia pacing, including adaptive rate pacing, to detect and treat bradyarrhythmias and to provide cardiac rate support after defibrillation therapy. Boston Scientific implantable cardioverter defibrillators (ICDs) are indicated to provide ventricular antitachycardia pacing (ATP) and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias

FDA Enforcement
Class II ·Terminated·Boston Scientific CRM Corp·October 29, 2014